Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Completed

Conditions studied: Neovascular Age-related Macular Degeneration

In brief

This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.

Key facts

Study ID

NCT05131646

Run by

Clearside Biomedical, Inc.

People needed

15

Starts

2021-10-08

Expected to finish

2023-01-05

Last updated by the study team

2024-03-04

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrolled in and completed the Parent study, CLS1002-101, as part of Cohort 2 or Cohort 3 or Cohort 4.

You may not qualify if…

• Received prohibited medication in the Parent study, CLS1002-101.
• Enrolled in the Parent study CLS1002-101 as part of Cohort 1.
• Females of childbearing potential who are pregnant and or lactating.

Where it is running

• Retinal Consultants of Arizona — Phoenix, Arizona, United States
• Northern California Retina Vitreous Associates Medical Group, LLC — Mountain View, California, United States
• Retina Consultants Medical Group, Inc — Sacramento, California, United States
• Southeast Retina Center — Augusta, Georgia, United States
• Cumberland Valley Retina Consultants — Hagerstown, Maryland, United States
• Retina Consultants of Texas — Bellaire, Texas, United States
• Retina Consultants of Texas — The Woodlands, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.